Characterization of a thymidine kinase-deficient mutant of equine herpesvirus 4 and in vitro susceptibility of the virus to antiviral agents

Antiviral Research

Volumn 85, Issue 2, 2010, Pages 389-395

  Azab, Walid ^a   Tsujimura, Koji ^b   Kato, Kentaro ^a   Arii, Jun ^a   Morimoto, Tomomi ^c   Kawaguchi, Yasushi ^c   Tohya, Yukinobu ^a   Matsumura, Tomio ^b   Akashi, Hiroomi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b EQUINE RESEARCH INSTITUTE   (Japan)

^c THE UNIVERSITY OF TOKYO   (Japan)

Author keywords

Antiviral drugs; EHV 4; TK

Indexed keywords

ACICLOVIR; GANCICLOVIR; THYMIDINE KINASE;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; CONTROLLED STUDY; DELETION MUTANT; DRUG EFFECT; DRUG POTENCY; EMBRYO; ENZYME ACTIVITY; ENZYME DEFICIENCY; EQUINE HERPES VIRUS; FEASIBILITY STUDY; FETUS; HORSE DISEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; MUTAGENESIS; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; VIRUS CELL TRANSFORMATION; VIRUS CULTURE; VIRUS GENOME; VIRUS INHIBITION; VIRUS MUTANT; VIRUS PLAQUE; VIRUS REPLICATION; VIRUS TITRATION;

ACYCLOVIR; ANIMALS; ANTIVIRAL AGENTS; CELL LINE; GANCICLOVIR; GENE DELETION; HERPESVIRUS 4, EQUID; HUMANS; MICROBIAL SENSITIVITY TESTS; PLAQUE ASSAY; THYMIDINE KINASE; VIRAL PROTEINS;

BACTERIA (MICROORGANISMS); EQUID HERPESVIRUS 1; EQUID HERPESVIRUS 4; EQUIDAE;

EID: 74449083237     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2009.11.007     Document Type: Article

References (45)

1. Allen G.P., and Bryans J.T. Molecular epizootiology, pathogenesis, and prophylaxis of equine herpesvirus-1 infections. Prog. Vet. Microbiol. Immunol. 2 (1986) 78-144
2. Azab W., Kato K., Arii J., Tsujimura K., Yamane D., Tohya Y., Matsumura T., and Akashi H. Cloning of the genome of equine herpesvirus 4 strain TH20p as an infectious bacterial artificial chromosome. Arch. Virol. 154 (2009) 833-842
3. Boyd M., Safrin S., and Kern E. Penciclovir: a review of its spectrum of activity, selectivity, and cross-resistance pattern. Antiviral Chem. Chemother. 4 Suppl. 1 (1993) 3-11
4. Coen D.M., Kosz-Vnenchak M., Jacobson J.G., Leib D.A., Bogard C.L., Schaffer P.A., Tyler K.L., and Knipe D.M. Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 4736-4740
5. Cornick J., Martens J., Martens R., Crandell R., McConnell S., and Kit S. Safety and efficacy of a thymidine kinase negative equine herpesvirus-1 vaccine in young horses. Can. J. Vet. Res. 54 (1990) 260-266
6. Davison A.J., Eberle R., Ehlers B., Hayward G.S., McGeoch D.J., Minson A.C., Pellett P.E., Roizman B., Studdert M.J., and Thiry E. The order Herpesvirales. Arch. Virol. 154 (2009) 171-177
7. De Clercq E. Trend in the development of new antiviral agents for the chemotherapy of infections caused by herpesviruses and retroviruses. Rev. Med. Virol. 5 (1995) 149-164
8. De Clercq E., Brancale A., Hodge A.V., and Field H.J. Antiviral Chemistry & Chemotherapy's current antiviral agents FactFile 2006 (1st edition). Antiviral Chem. Chemother. 17 (2006) 113-166
9. Field H.J., and Whitley R.J. Antiviral chemotherapy. In: Mahy B.W.J., and Meulen V. (Eds). Topley & Wilson's Microbiology and Microbial Infections. 10th ed. (2005), Hodder Arnold, London 1605-1645
10. Field H.J., and Wildy P. The pathogenicity of thymidine kinase-deficient mutants of herpes simplex virus in mice. J. Hyg. 81 (1978) 267-277
11. Focher F., Lossani A., Verri A., Spadari S., Maioli A., Gambino J.J., Wright G.E., Eberle R., Black D.H., Medveczky P., Medveczky M., and Shugar D. Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides. Antimicrob. Agents Chemother. 51 (2007) 2028-2034
12. Garré B., Shebany K., Gryspeerdt A., Baert K., van der Meulen K., Nauwynck H., Deprez P., De Backer P., and Croubels S. Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. Antimicrob. Agents Chemother. 51 (2007) 4308-4314
13. Garré B., van der Meulen K., Nugent J., Neyts J., Croubels S., De Backer P., and Nauwynck H. In vitro susceptibility of six isolates of equine herpesvirus 1 to acyclovir, ganciclovir, cidofovir, adefovir, PMEDAP and foscarnet. Vet. Microbiol. 122 (2007) 43-51
14. Han M.G., Kweon C.H., Mo I.P., and Kim S.J. Pathogenicity and vaccine efficacy of a thymidine kinase gene deleted infectious laryngotracheitis virus expressing the green fluorescent protein gene. Arch. Virol. 147 (2002) 1017-1031
15. Harless W., and Pusterla N. Equine herpesvirus 1 and 4 respiratory disease in the horse. Clin. Techn. Equine Pract. 5 (2006) 197-202
16. Heintz N. BAC to the future: the use of bac transgenic mice for neuroscience research. Nat. Rev. Neurosci. 2 (2001) 861-870
17. Henninger, R., 2003. Epidemic neurological disease due to equine herpesvirus 1. Presented at the International Veterinary Emergency and Critical Care Symposium 9th Annual Meeting, New Orleans, LA. The University of Findlay English Equestrian Center, pp. 621-624.
18. Hussein I.T., Menashy R.V., and Field H.J. Penciclovir is a potent inhibitor of feline herpesvirus-1 with susceptibility determined at the level of virus-encoded thymidine kinase. Antiviral Res. 78 (2008) 268-274
19. Jenssen H., Andersen J.H., Mantzilas D., and Gutteberg T.J. A wide range of medium-sized, highly cationic, alpha-helical peptides show antiviral activity against herpes simplex virus. Antiviral Res. 64 (2004) 119-126
20. Kawakami Y., Kaji T., Ishizaki R., Shimizu T., and Matumoto M. Etiologic study on an outbreak of acute respiratory disease among colts due to equine rhinopneumonitis virus. Jpn. J. Exp. Med. 32 (1962) 211-229
21. Kit S., Kit M., and Pirtle E.C. Attenuated properties of thymidine kinase-negative deletion mutant of pseudorabies virus. Am. J. Vet. Res. 46 (1985) 1359-1367
22. Kit S., Qavi H., Gaines J.D., Billingsley P., and McConnell S. Thymidine kinase-negative bovine herpesvirus type 1 mutant is stable and highly attenuated in calves. Arch. Virol. 86 (1985) 63-83
23. Landry M.L., Stanat S., Biron K., Brambilla D., Britt W., Jokela J., Chou S., Drew W.L., Erice A., Gilliam B., Lurain N., Manischewitz J., Miner R., Nokta M., Reichelderfer P., Spector S., Weinberg A., Yen-Lieberman B., Crumpacker C., Group, and t.A.C.T.G.C.R.W. A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates. Antimicrob. Agents Chemother. 44 (2000) 688-692
24. Lee E.C., Yu D., Martinez de Velasco J., Tessarollo L., Swing D.A., Court D.L., Jenkins N.A., and Copeland N.G. A highly efficient Escherichia coli-based chromosome engineering system adapted for recombinogenic targeting and subcloning of BAC DNA. Genomics 73 (2001) 56-65
25. Maeda K., Mizukoshi F., Hamano M., Kai K., Iwata H., Kondo T., and Matsumura T. Development of an equine herpesvirus type 4-specific enzyme-linked immunosorbent assay using a B-cell epitope as an antigen. J. Clin. Microbiol. 42 (2004) 1095-1098
26. Matsumura T., Sugiura T., Imagawa H., Fukunaga Y., and Kamada M. Epizootiological aspects of type 1 and type 4 equine herpesvirus infections among horse populations. J. Vet. Med. Sci. 54 (1992) 207-211
27. McGregor S., Easterday B.C., Kaplan A.S., and Ben-Porat T. Vaccination of swine with thymidine kinase-deficient mutants of pseudorabies virus. Am. J. Vet. Res. 46 (1985) 1494-1497
28. Mittal S.K., and Field H.J. Analysis of the bovine herpesvirus type 1 thymidine kinase (TK) gene from wild-type virus and TK-deficient mutants. J. Gen. Virol. 70 (1989) 901-918
29. Morfin F., and Thouvenot D. Herpes simplex virus resistance to antiviral drugs. J. Clin. Virol. 26 (2003) 29-37
30. Patel J.R., and Heldens J. Equine herpesviruses 1 (EHV-1) and 4 (EHV-4)-epidemiology, disease and immunoprophylaxis: a brief review. Vet. J. 170 (2005) 14-23
31. Reed S.M., and Toribio R.E. Equine herpesvirus 1 and 4. Vet. Clin. North Am. Equine Pract. 20 (2004) 631-642
32. Roizman B. Herpesviridae. In: Field B.N., Knipe D.M., Howley P.M., Channock R.M., Melnick J.L., Monath T.P., Roizman B., and Straus S.E. (Eds). Virology. third ed. (1996), Lippincott-Raven, Philadelphia, NY
33. Rollinson E.A., and White G. Relative activities of acyclovir and BW759 against Aujeszky's disease and equine rhinopneumonitis viruses. Antimicrob. Agents Chemother. 24 (1983) 221-226
34. Sergerie Y., and Boivin G. Thymidine kinase mutations conferring acyclovir resistance in herpes simplex type 1 recombinant viruses. Antimicrob . Agents Chemother. 50 (2006) 3889-3892
35. Shizuya H., and Kouros-Mehr H. The development and applications of the bacterial artificial chromosome cloning system. Keio J. Med. 50 (2001) 26-30
36. Sinzger C., Knapp J., Schmidt K., Kahl M., and Jahn G. A simple and rapid method for preparation of viral DNA from cell associated cytomegalovirus. J. Virol. Methods 81 (1999) 115-122
37. Slater J.D., Gibson J.S., and Field H.J. Pathogenicity of a thymidine kinase-deficient mutant of equine herpesvirus 1 in mice and specific pathogen-free foals. J. Gen. Virol. 74 (1993) 819-828
38. Slater J.D., Lunn D.P., Horohov D.W., Antczak D.F., Babiuk L., Breathnach C., Chang Y.W., Davis-Poynter N., Edington N., Ellis S., Foote C., Goehring L., Kohn C.W., Kydd J., Matsumura T., Minke J., Morley P., Mumford J., Neubauer T., O'Callaghan D., Osterrieder K., Reed S., Smith K., Townsend H., Meulen K.v.d., Whalley M., and Wilson W.D. Report of the equine herpesvirus-1 Havermeyer Workshop, San Gimignano, Tuscany, June 2004. Vet. Immunol. Immunopathol. 111 (2006) 3-13
39. Stanberry L.R., Kit S., and Myers M.G. Thymidine kinase-deficient herpes simplex virus type 2 genital infection in guinea pigs. J. Virol. 55 (1985) 322-328
40. Tearle J.P., Smith K.C., Platt A.J., Hannant D., Davis-Poynter N.J., and Mumford J.A. In vitro characterisation of high and low virulence isolates of equine herpesvirus-1 and -4. Res. Vet. Sci. 75 (2003) 83-86
41. Telford E.A., Watson M.S., Perry J., Cullinane A.A., and Davison A.J. The DNA sequence of equine herpesvirus-4. J. Gen. Virol. 79 (1998) 1197-1203
42. Tischer B.K., von Einem J., Kaufer B., and Osterrieder N. Two-step red-mediated recombination for versatile high-efficiency markerless DNA manipulation in Escherichia coli. Biotechniques 40 (2006) 191-197
43. van der Meulen K., Garré B., Croubels S., and Nauwynck H. In vitro comparison of antiviral drugs against feline herpesvirus 1. BMC Vet. Res. 2 (2006) 13
44. van der Meulen K.M., Vercauteren G., Nauwynck H.J., and Pensaert M.B. A local epidemic of equine herpesvirus 1-induced neurological disorders in Belgium. Flem. Vet. J. 72 (2003) 366-372
45. Zhang Z., Huang Y., and Zhu H. A highly efficient protocol of generating and analyzing VZV ORF deletion mutants based on a newly developed luciferase VZV BAC system. J. Virol. Methods 148 (2008) 197-204